Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04275700
Other study ID # 09182018-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2018
Est. completion date September 1, 2024

Study information

Verified date May 2023
Source Center for Human Reproduction
Contact David Barad, MD
Phone 212 944-4400
Email dbarad@theCHR.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The hypothesis of the study is that ovaries of women with a history of poor response to ovulation induction may benefit from exposure to growth factors known to be present in Platelet Rich Plasma (PRP). Since even ovaries from women with poor response still contain primordial follicles (which, however, no longer undergo recruitment), it is hoped that PRP injections into ovaries will activate follicular recruitment pathways and, subsequently, result in follicle growth. Should such growth be observed, follicles will be supported with routine daily gonadotropin stimulation until hCG trigger.


Description:

The hypothesis of the study is that ovaries of women with a history of poor response to ovulation induction may benefit from exposure to growth factors known to be present in PRP. Autologous Platelet Rich Plasma (A-PRP) is plasma with a concentration of platelets above the blood baseline. A-PRP is developed from autologous blood. Within A-PRP, the concentration of platelets delivers an increased number of growth factors. In this study A-PRP will be prepared using Regen Lab PRP Kit which is approved by US-FDA for preparation of PRP. PRP is becoming widely used in a variety of medical procedures seeking tissue remodeling and/or healing as an intervention. To date, applications in orthopedics, wound healing, dermatology and plastic surgery have gained general acceptance, primarily as the role of platelets and their activation in tissue repair and recovery has become better understood at a cellular and molecular level. This knowledge base provides a foundation for the present study because of the ready availability of FDA-approved kits for autologous PRP preparations and the recognition that the aging ovary acquires tissue pathologies in the form of wound healing and fibrosis as a result of repeat ovulations over the reproductive lifespan of women. Since PRP is an autologous blood product, and is widely used via injection into various organs and tissues, safety concerns are minimal. This study will involve only adult women with a diagnosis of diminished ovarian reserve. All consenting participants will receive injections of autologous Platelet RIch Plasma (A-PRP) in both ovaries under ultrasound guidance performed after induction of IV sedation. Assumption of this study is that in women with previous poor response to ovulation induction will show limited follicle growth. The study will try to estimate effect of PRP on this condition by comparing post-PRP response to the previous response. The investigators recognize that there will be a possibility of apparent response based on regression to the mean. The investigators expect that study of fifty patients should be enough to determine if there is a potential clinical effect and to allow estimation of that effect for power calculations for future studies.


Recruitment information / eligibility

Status Recruiting
Enrollment 66
Est. completion date September 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 21 Years to 52 Years
Eligibility Inclusion Criteria: - Women with failure to respond well to ovulation induction by having fewer than 1 cleavage stage embryo in response to past ovulation induction who do not qualify for the PRP4POI study - Age 54 years and under. - FSH > 12 - AMH < 1.1 - -No Aspirin or Motrin for one week before treatment Exclusion Criteria: - Age > 54 years - Marked thrombocytopenia - Blood diseases - Hypofibrinogenemia - Hemodynamic instability - Anticoagulant or antiaggregant treatment - Oncological diseases (specially, skeletal system and blood) - Sepsis - Acute and chronic infectious diseases - Autoimmune diseases, for example, lupus erythematosus, etc. Relative contraindications for PRP - Chronic liver diseases in the exacerbation phase - Chronic intoxication against the background of long-term use of alcohol, addictive drugs, an administration of potent medications - Use of steroidal anti-inflammatory drugs in less than 2 days before drawing the blood, an injection of corticosteroids in little less than 2 weeks before the procedure - Pregnancy - Inflammatory skin diseases, chronic dermatosis in the exacerbation phase, for example, psoriasis, atopic eczema, etc.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
A-PRP
The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.

Locations

Country Name City State
United States Center For Human Reproduction New York New York

Sponsors (1)

Lead Sponsor Collaborator
Center for Human Reproduction

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Emergence of new ovarian follicles with evidence of estradiol production Emergence of new ovarian follicles greater than 4 mm in average diameter as measured using pelvic sonography with evidence of change estradiol serum estradiol levels as measured using a immuno assay. Change from baseline to 12 weeks
Secondary Change in serum AMH Increase in serum AMH from baseline level as measured using an immuno assay Change from baseline to 12 weeks
Secondary Number of participants with retrieval of oocytes in an IVF cycle Number of participants with retrieval of oocytes in an IVF cycle 6 months
Secondary Number of participants that establish a Clinical Pregnancy Number of participants that establish a Clinical Pregnancy 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04972877 - Effect of Electro-acupuncture on Women With Diminished Ovarian Reserve N/A
Recruiting NCT04447872 - The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol N/A
Recruiting NCT05277948 - Effect of Thumbtack Needle on Ovarian Function of Women With Diminished Ovarian Reserve (DOR) N/A
Recruiting NCT04711772 - Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve
Recruiting NCT03670407 - Follicular Activation by Fragmentation of Ovarian Tissue N/A
Recruiting NCT06072794 - A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI) Phase 1
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Not yet recruiting NCT02099916 - Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF Phase 2/Phase 3
Not yet recruiting NCT06081257 - The Effect of "KB-120" Small Molecular Nutrient in Women With Decreased Ovarian Reserve N/A
Recruiting NCT06426355 - The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR N/A
Recruiting NCT06223178 - Efficacy of Thumb-tack Needle Treatment for Diminished Ovarian Reserve N/A
Not yet recruiting NCT05577455 - Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients Phase 3
Not yet recruiting NCT05459493 - A Clinical Study of Chinese Herbal Compound TJAOA101 in Therapy of Diminished Ovarian Reserve Early Phase 1
Recruiting NCT05665010 - Precise Stratification of Genetic Risk of Ovarian Function Impairment
Not yet recruiting NCT05385848 - Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study N/A
Terminated NCT01614067 - Delayed Start to Ovarian Stimulation Phase 4
Recruiting NCT06395623 - Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics
Recruiting NCT05847283 - DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT N/A
Recruiting NCT05485610 - Effect of NMN (Nicotinamide Mononucleotide) on Diminished Ovarian Reserve (Including Premature Ovarian Insufficiency) N/A
Completed NCT04237909 - Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency N/A